Literature DB >> 18804493

Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.

Luis Arnés1, Paola Moreno, Bernardo Nuche-Berenguer, Isabel Valverde, Maria L Villanueva-Peñacarrillo.   

Abstract

Exendin-4, like GLP-1, is insulinotropic, antidiabetic and glucoregulatory among other properties, which are thought to be exerted through the pancreatic GLP-1 receptor; exendin-4 is also an agonist of the GLP-1 stimulatory action upon liver and muscle glucose metabolism, where GLP-1 receptor is distinct from that in the pancreas. We investigated the action of prolonged treatment with exendin-4 upon glucose transport parameters in skeletal muscle and liver of normal rats and streptozotocin-induced type 2 diabetic rats (T2D). Muscle of T2D showed lower than normal glucose transport; exendin-4 did not modify the value in normal but normalized that in the T2D; unlike previously detected with GLP-1, no apparent modification was observed in GLUT-4 expression in either group after exendin-4, except for an increased GLUT-4 protein in normal rats. Yet, exendin-4 significantly stimulated liver GLUT-2-mRNA and -protein in T2D and normal rats, the effect upon GLUT-2-protein in T2D being higher than that in normal animals; this was accompanied by a normalizing action of exendin-4 upon the lower than normal liver glycogen in T2D rats. These data suggest that the liver may represent at least one of the major target organs for exendin-4 to exert its plasma lowering effect in diabetic state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18804493     DOI: 10.1016/j.regpep.2008.08.005

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  11 in total

Review 1.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

2.  Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Authors:  Nitika Arora Gupta; Jamie Mells; Richard M Dunham; Arash Grakoui; Jeffrey Handy; Neeraj Kumar Saxena; Frank A Anania
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

3.  Enhanced Incretin Effects of Exendin-4 Expressing Chimeric Plasmid Based On Two-Step Transcription Amplification System with Dendritic Bioreducible Polymer for the Treatment of Type 2 Diabetes.

Authors:  Pyung-Hwan Kim; Minhyung Lee; Kihoon Nam; Sung Wan Kim
Journal:  J Gene Ther       Date:  2013-12-01

4.  Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.

Authors:  Jinmi Lee; Seok-Woo Hong; Seoung Wan Chae; Dong Hoon Kim; Ji Hun Choi; Ji Cheol Bae; Se Eun Park; Eun-Jung Rhee; Cheol-Young Park; Ki-Won Oh; Sung-Woo Park; Sun-Woo Kim; Won-Young Lee
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

5.  In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.

Authors:  Sha Liao; Yuanjun Liang; Zhiwei Zhang; Jinglai Li; Juan Wang; Xiaoying Wang; Guifang Dou; Zhenqing Zhang; Keliang Liu
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

6.  Exendin-4 protects mice from D-galactose-induced hepatic and pancreatic dysfunction.

Authors:  Akram Ahangarpour; Ali Akbar Oroojan; Mohammad Badavi
Journal:  Pathobiol Aging Age Relat Dis       Date:  2017-12-26

7.  Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.

Authors:  Cuiwei Chen; Hongyue Zheng; Junjun Xu; Xiaowei Shi; Fanzhu Li; Xuanshen Wang
Journal:  Daru       Date:  2017-09-04       Impact factor: 3.117

8.  Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.

Authors:  Yeonhee Hong; Jong Han Lee; Kwang Won Jeong; Cheol Soo Choi; Hee-Sook Jun
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-04-24       Impact factor: 12.910

9.  Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes.

Authors:  Mari Cassol Ferreira; Maria Elizabeth Rossi da Silva; Rosa Tsuneshiro Fukui; Maria do Carmo Arruda-Marques; Salman Azhar; Rosa Ferreira Dos Santos
Journal:  Diabetol Metab Syndr       Date:  2019-01-25       Impact factor: 3.320

10.  Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression.

Authors:  Tram Thi Ngoc Nguyen; Hojung Choi; Hee-Sook Jun
Journal:  Front Pharmacol       Date:  2020-02-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.